Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Saved in:
| Title: | Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) |
|---|---|
| Authors: | Bhattoa, Harjit Pal, Vasikaran, Samuel, Trifonidi, Ioulia, Kapoula, Georgia, Lombardi, Giovanni, Jørgensen, Niklas Rye, Pikner, Richard, Miura, Masakazu, Chapurlat, Roland, Hiligsmann, Mickael, Haarhaus, Mathias, Evenepoel, Pieter, Jørgensen, Hanne Skou, Herrmann, Markus, Kaufman, Jean-Marc, Clark, Patricia, Tuzun, Şansın, Al-Daghri, Nasser, Silverman, Stuart, Alokail, Majed S, Ormarsdóttir, Sif, Yerro, María Concepción Prieto, Matijevic, Radmila, Laslop, Andrea, da Silva Rosa, Mario Miguel Coelho, Zakraoui, Leith, Burlet, Nansa, McCloskey, Eugene, Harvey, Nicholas C, Radermecker, Régis, Fusaro, Maria, Torre, Carla, Kanis, John A, Rizzoli, René, Reginster, Jean-Yves, Makris, Konstantinos, Cavalier, Etienne |
| Contributors: | İstanbul University Cerrahpaşa Institutional Repository, University of Debrecen |
| Source: | Osteoporos Int Bhattoa, H P, Vasikaran, S, Trifonidi, I, Kapoula, G, Lombardi, G, Jørgensen, N R, Pikner, R, Miura, M, Chapurlat, R, Hiligsmann, M, Haarhaus, M, Evenepoel, P, Jørgensen, H M S, Herrmann, M, Kaufman, J M, Clark, P, Tuzun, Ş, Al-Daghri, N, Silverman, S, Alokail, M S, Ormarsdóttir, S, Yerro, M C P, Matijevic, R, Laslop, A, Rosa, M M C D S, Zakraoui, L, Burlet, N, McCloskey, E, Harvey, N C, Radermecker, R P, Fusaro, M, Torre, C, Kanis, J A, Rizzoli, R, Reginster, J Y, Makris, K & Cavalier, E 2025, 'Update on the role of bone turnover markers in the diagnosis and management of osteoporosis : a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)', Osteoporosis International, vol. 36, no. 4, 513925, pp. 579-608. https://doi.org/10.1007/s00198-025-07422-3 Bhattoa, H P, Vasikaran, S, Trifonidi, I, Kapoula, G, Lombardi, G, Jørgensen, N R, Pikner, R, Miura, M, Chapurlat, R, Hiligsmann, M, Haarhaus, M, Evenepoel, P, Jørgensen, H S, Herrmann, M, Kaufman, J-M, Clark, P, Tuzun, Ş, Al-Daghri, N, Silverman, S, Alokail, M S, Ormarsdóttir, S, Yerro, M C P, Matijevic, R, Laslop, A, da Silva Rosa, M M C, Zakraoui, L, Burlet, N, McCloskey, E, Harvey, N C, Radermecker, R P, Fusaro, M, Torre, C, Kanis, J A, Rizzoli, R, Reginster, J-Y, Makris, K & Cavalier, E 2025, ' Update on the role of bone turnover markers in the diagnosis and management of osteoporosis : a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) ', Osteoporosis International, vol. 36, no. 4, pp. 579-608 . https://doi.org/10.1007/s00198-025-07422-3 Bhattoa, H P, Vasikaran, S, Trifonidi, I, Kapoula, G, Lombardi, G, Jørgensen, N R, Pikner, R, Miura, M, Chapurlat, R, Hiligsmann, M, Haarhaus, M, Evenepoel, P, Jørgensen, H S, Herrmann, M, Kaufman, J M, Clark, P, Tuzun, Ş, Al-Daghri, N, Silverman, S, Alokail, M S, Ormarsdóttir, S, Yerro, M C P, Matijevic, R, Laslop, A, da Silva Rosa, M M C, Zakraoui, L, Burlet, N, McCloskey, E, Harvey, N C, Radermecker, R P, Fusaro, M, Torre, C, Kanis, J A, Rizzoli, R, Reginster, J Y, Makris, K & Cavalier, E 2025, 'Update on the role of bone turnover markers in the diagnosis and management of osteoporosis : a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)', Osteoporosis International, vol. 36, no. 4, pp. 579-608. https://doi.org/10.1007/s00198-025-07422-3 |
| Publisher Information: | Springer Science and Business Media LLC, 2025. |
| Publication Year: | 2025 |
| Subject Terms: | Procollagen/blood, CHRONIC KIDNEY-DISEASE, Peptides/blood, Endocrinology, Diabetes and Metabolism, 4202 Epidemiology, Osteoporotic Fractures/etiology, N-TERMINAL PROPEPTIDE, beta-CTX-I, 0903 Biomedical Engineering, Osteoporosis/therapy, Human health sciences, Bone Density Conservation Agents, Osteoporosis/diagnosis, procollagen Type I N-terminal peptide, ß-CTX-I, Bone Remodeling/physiology, POSTMENOPAUSAL WOMEN, Position Paper, Bone Remodeling, Osteoporosis/physiopathology, Bone turnover markers, Life Sciences & Biomedicine, Procollagen, Osteoporosis/drug therapy, I PROCOLLAGEN PINP, Bone Density Conservation Agents/therapeutic use, Consensus, Collagen Type I/blood, β-CTX-I, Public health, health care sciences & services, Osteoporosis/blood, Bone status indices, Sciences de la santé humaine, Risk Assessment, Santé publique, services médicaux & soins de santé, AGE-RELATED-CHANGES, Collagen Type I, 1117 Public Health and Health Services, Endocrinology & Metabolism, SERUM OSTEOPROTEGERIN LEVELS, Humans, collagen type I trimeric cross-linked peptide, Risk Assessment/methods, BIOCHEMICAL MARKERS, Science & Technology, Osteoporotic Fractures/prevention & control, 3202 Clinical sciences, 1103 Clinical Sciences, TRACP5b, Peptide Fragments, PINP, Osteoporosis, REFERENCE INTERVALS, MINERAL DENSITY, Peptide Fragments/blood, BALP, Peptides, Biomarkers/blood, Biomarkers, Osteoporotic Fractures, GROWTH-FACTOR 23 |
| Description: | The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis.Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined.Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications.We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis. |
| Document Type: | Article Other literature type |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 1433-2965 0937-941X |
| DOI: | 10.1007/s00198-025-07422-3 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/40152990 https://cris.maastrichtuniversity.nl/en/publications/acf11ebf-2ab3-4a07-98f2-2e687a89dfbb https://doi.org/10.1007/s00198-025-07422-3 https://hdl.handle.net/20.500.12831/27042 https://doi.org/10.1007/s00198-025-07422-3 https://hdl.handle.net/2268/334682 https://doi.org/10.1007/s00198-025-07422-3 https://pergamos.lib.uoa.gr/uoa/dl/object/3498391 https://curis.ku.dk/ws/files/452215655/s00198-025-07422-3.pdf http://www.scopus.com/inward/record.url?scp=105001872684&partnerID=8YFLogxK https://doi.org/10.1007/s00198-025-07422-3 https://pure.au.dk/portal/en/publications/c06bf694-f1fd-400b-9b38-53c4223ed5dd |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) . |
| Accession Number: | edsair.doi.dedup.....69a6784f4a64a43908da268463d4c9f2 |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis.Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined.Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications.We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis. |
|---|---|
| ISSN: | 14332965 0937941X |
| DOI: | 10.1007/s00198-025-07422-3 |